Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Centaurus Biopharma Co., Ltd.

Other

Medshine Discovery Inc.

Shouyao Holdings (beijing) Co., Ltd.

Advenchen Laboratories Nanjing Ltd

Chia Tai Tianqing Pharmaceutical Group Go., Ltd.

Xin Tian

Xiquan Zhang

Ling Yang

Hongjiang Xu

Hui Zhang

Kevin X Chen

Yong Peng

Yongxin Han

Fei Liu

Yuandong Hu

Shanchun Wang

Shuhui Chen

Xunqiang Wang

Chunli Shen

Xiangjian Wang

Shenglin Chen

Li Zhu

Chengde Wu

Jian Xiong

Rui Zhao

Aiming Zhang

Cheng Xie

Yanqing Yang

Zhao Yang

Xiongbin Xu

Liguang Dai

Zhilin Chen

Xiaowei Duan

Song Tang

Jie Dai

Xiaole Zhan

Jian Li

Ting Wang

Yu Wang

Kai Zhou

Lin Zhang

Na Zhao

Yan Zhu

Zhongmin Maxwell Wang

Hong Luo

Dengming Xiao

Rong Li

Zhen Gong

Xijie Liu

Yinghui Sun

Boyu Hu

Yizhong Zhu

Linghui Wu

Yanxin Yu

Chang Lu

Jiahu Wu

Shulong Wang

Huting Wang

Hongmei Gu

Zheng Liu

Jijun Li

Hai Jiang

Weiwei Feng

Peng Lv

Qin Yan

Xianxing Shang

Yeliu Wang

Chen Shen

Xiaoping Jin

Peng Lyu

Yuing Guo

Tianqing Chu

Baohui Han

Weinan He

Hua Zhong

Xuejin Zhang

Zhulian Jiang

Jie Zhou

Haomin Chen

Jiangfeng Lin

Xiaoyuan Chen

The present application provides a therapeutic combination of a quinoline derivative and an antibody, which comprises an immune checkpoint inhibitor and a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is a compound of formula I or a pharmaceutically acceptable salt thereof. The therapeutic combination in the present application shows good activity against lung tumor and liver tumor.

Therapeutic combination of quinoline derivative and antibody

The present application belongs to the field of medicine, and in particular relates to a crystal of a diarylthiohydantoin compound, a preparation method therefor, and use thereof in the preparation of medicaments for treating related diseases which are androgen-mediated.

Crystal of diarylthiohydantoin compound

The present invention relates to a iminosulfanone compound represented by formula (I) as a bromodomain protein inhibitor and a pharmaceutically acceptable salt thereof and to a preparation method, pharmaceutical composition, and medical use thereof.

Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof

The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.

Diarylthiohydantoin compound as androgen receptor antagonist

The present invention provides a quinoline derivative for treating triple-negative breast cancer and use thereof in preparing a pharmaceutical composition for treating a tumor. Specifically, the present invention relates to use of quinoline derivative 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropylamine in the treatment of triple-negative breast cancer, 

Quinoline derivative for treatment of triple-negative breast cancer

A bicyclic compound acting as a ROR&#x3b3; inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compound of formula (I-A) or formula (I-B) or pharmaceutically acceptable salt thereof has good ROR&#x3b3; inhibitory activities, being expected to be used for treating diseases mediated by ROR&#x3b3; receptors in a mammal. 

Bicylic compound acting as an inhibitor

A borate compound of an azetidine derivative, relating in particular to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a tautomer thereof, a stereoisomer thereof or a geometric isomer thereof, as well as a use thereof in the preparation of a drug used for the treatment or prevention of multiple myeloma. 

Borate of azetidine derivative

An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation induced cancer. 

Iridinesulfonamide compound and use method thereof

Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers. 

Sultam compound and application method thereof

Disclosed in the present application are a compound represented by formula (I), or a pharmaceutically acceptable salt, a tautomer thereof, a stereoisomer thereof, or a geometrical isomer thereof, and uses thereof in the preparation of drugs for treating or preventing multiple myeloma. 

Azetidine derivative

Disclosed are a crystal of a maleate of a compound of formula (I), a preparation method for the crystal, a crystallization composition of same, a pharmaceutical composition of same, and uses thereof in preventing and treating a tumor. 

Crystal of salt of quinazoline derivative

The present application relates to maleates of a compound of Formula I, methods for preparing the same, pharmaceutical compositions thereof and uses thereof in the treatment of tumors, such as non-small cell lung cancer, breast cancer, and other malignant tumors. 

Salts of quinazoline derivative and method for preparing the same

The present invention addresses methods and uses of quinoline derivatives in the treatment of tumors and pharmaceutical compositions for treatment of same. Specifically, the present invention involves a method and applications for the use of the quinoline derivative 1-[[[4-(4-fluoro-2-methyl-H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same.

Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same

The present application relates to compounds represented by general formula (I), general formula (II) or general formula (III), and pharmaceutically acceptable salts or hydrates thereof, preparation methods thereof, and pharmaceutical compositions thereof. The compounds represented by general formula (I), general formula (II) or general formula (III) have inhibitory activities against isocitrate dehydrogenase 2 (IDH2), thereby being capable of treating IDH2 mutation-induced cancers. 

Antitumor compound targeting IDH2 mutation and method of use thereof

Growing community of inventors

Lianyungang, China

Xin Tian